AB001 is a novel PSMA-targeted radioligand therapy designed to treat metastatic prostate cancer with potentially higher tumor dose rates and lower normal tissue toxicity. The phase 1 trial will enroll ...

William C. Huang, MD, highlights data from a long-term extension study of the OPTIMA II trial. In a recent interview with Urology Times®, William C. Huang, MD, outlined the key findings and ...

IDE397 combined with sacituzumab govitecan showed promising efficacy in MTAP-deletion urothelial carcinoma, with high disease control rates in both dose cohorts. The combination therapy's efficacy ...

Cretostimogene grenadenorepvec shows a 24-month complete response rate of 41.8% in high-risk BCG-unresponsive NMIBC patients, with 90% of 12-month responders maintaining CR. The BOND-003 trial ...

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Alpha DaRT technology diffuses alpha-emitting atoms within tumors, overcoming alpha particles' short travel range limitation. The technology shows promise in prostate and bladder cancer, offering ...

The Signatera ctDNA test predicts which MIBC patients benefit from adjuvant atezolizumab, showing significant DFS and OS improvements in MRD-positive patients. The IMvigor011 trial enrolled 760 ...

Joseph Song, MD, discusses his approach to patient selection for the SURE procedure, particularly in comparison to more invasive options such as PCNL. The emergence of new aspiration devices for stone ...

Continuation of ARPI with [177Lu]Lu-PSMA-617 in ARPI-refractory mCRPC patients does not improve PSA response or overall survival. Patients receiving ARPI were more likely to complete all treatment ...

BOTRESO (MCS-2) showed significant LUTS improvement in Asian populations and was well-tolerated in phase 3 trials for BPH. MCS-8 demonstrated reduced rates of positive prostate biopsies and high-grade ...

Sulopenem etzadroxil and probenecid (Ornlyvah) is the first oral penem antibiotic approved in the US for uUTIs in adult women with limited treatment options. Clinical trials demonstrated sulopenem's ...

AI model detects early signs of prostate cancer in biopsies before histological changes are apparent, outperforming pathologists in over 80% of cases. The study involved 213 patients, with the AI ...